Adrian Rawcliffe, Adaptimmune CEO at EUBIO22 (Rachel Kiki for Endpoints News)
August 2, 2024 04:08 AM EDTUpdated 04:16 PM
Cell/Gene Tx
FDA+

Adap­ti­m­mune gets FDA ac­cel­er­at­ed ap­proval for T cell re­cep­tor cell ther­a­py in rare soft tis­sue can­cer

Lei Lei Wu

News Reporter

The FDA grant­ed ac­cel­er­at­ed ap­proval to a cell ther­a­py for syn­ovial sar­co­ma, a rare type of can­cer typ­i­cal­ly found in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times